The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Background: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients. Methods: We here report on the combined antiviral effect of both drugs in a SARS-CoV-2 Syria...

Full description

Bibliographic Details
Main Authors: Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Arnab K. Chatterjee, Raf Mols, Patrick Augustijns, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:EBioMedicine
Subjects:
SARS-CoV-2
Antivirals
Molnupiravir
Favipiravir, hamsters, coronavirus
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421003881

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421003881

Similar Items